ArticleFrontiers in cardiovascular medicine2026
Phase entropy of gated SPECT-MPI for predicting major adverse cardiovascular events: incremental prognostic value beyond perfusion and function.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gated SPECT myocardial perfusion imaging (MPI) phase analysis provides a quantitative assessment of left ventricular mechanical synchrony, enabling cardiovascular risk stratification. Phase entropy, a derived imaging biomarker, reflects the spatiotemporal heterogeneity of myocardial contraction. However, its prognostic significance and clinically applicable threshold values have not been rigorously validated. This study aimed to determine the independent prognostic value of phase entropy for predicting major adverse cardiovascular events (MACE). Results: Among 1,674 coronary artery disease patients (median age 62.0 years, 66.2% male) followed for a median 36.6 months, an U-shaped association between phase entropy and major adverse cardiovascular events was identified ( Conclusion: Phase entropy ≤31% or >53% correlates with reduced survival. This biomarker independently predicts major adverse cardiovascular events and provides incremental prognostic value beyond TPD and LVEF, with ≤31% identifying a high-risk subgroup that merits intensified clinical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.